BC
BMRN icon

Brinker Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brinker Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.64M Buy
13,294
+507
+4% +$50.4K 0.05% 356
2020
Q1 		$1.08M Buy
12,787
+2,503
+24% +$216K 0.04% 402
2019
Q4 		$870K Buy
10,284
+83
+0.8% +$6.27K 0.03% 548
2019
Q3 		$688K Buy
+10,201
New +$786K 0.02% 607

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brinker Capital's BMRN Position: Q2 2020 in Review

Brinker Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 4% in Q2 2020, buying an estimated $50.4K and bringing the position to 13,294 shares worth $1.64M. The position accounts for 0.05% of the portfolio, ranked #356.

Brinker Capital first reported a position in BMRN in Q3 2019 and has held it in 4 quarters since. 528 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • Brinker Capital held 13,294 shares of BioMarin Pharmaceuticals worth $1.64M as of Q2 2020.
  • Brinker Capital bought 507 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $50.4K.
  • BioMarin Pharmaceuticals made up 0.05% of Brinker Capital's portfolio in Q2 2020, its #356 holding.
  • Brinker Capital first reported a position in BioMarin Pharmaceuticals in Q3 2019 and has held it in 4 quarters since.
  • 528 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.